Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Summary not available.
Philips reported first-quarter 2022 sales of EUR 3.9 billion, reflecting a 4% decline compared to Q1 2021. The company experienced a significant loss of EUR 152 million from continuing operations, worsening from a loss of EUR 34 million in the previous year. Adjusted EBITA dropped to 6.2% of sales. Despite challenges, including supply chain issues and the Respironics field action, order intake rose by 5%. Notably, Personal Health sales grew by 8%. Philips anticipates further growth in 2022 but acknowledges risks from geopolitical tensions and inflation.
Royal Philips (NYSE: PHG) has announced a notification regarding potential issues with its V60/V60 Plus and V680 ventilators manufactured by its subsidiary, Philips Respironics. The electrical circuit controlling the 35V power supply may cause silent shutdowns, risking respiratory assistance for patients. Philips recommends mitigation actions such as using an oxygen analyzer and ensuring alternative ventilation is available. The FDA has classified the recall as Class 1 in the U.S. Philips is committed to safety and will provide updates by June 30, 2022.
On April 21, 2022, Royal Philips announced the successful use of its CavaClear solution for removing embedded Inferior Vena Cava (IVC) filters in patients, marking the first application of this FDA-cleared technology. The CavaClear system assists in the safe ablation of tissue and removal of IVC filters that may pose long-term health risks. With estimates of over a million patients in the USA at risk from such filters, this innovation aims to improve patient outcomes and procedural efficiency. The device represents a significant advancement in treatment options for complex IVC filter retrieval.
On April 11, 2022, Royal Philips (NYSE: PHG) announced a strategic 10-year partnership with Oulu University Hospital in Finland. This collaboration aims to support the OYS2030 renewal program, which focuses on transforming the hospital's operations and facilities to enhance specialized care for Northern Finland's 750,000 residents. Philips will provide innovative diagnostic and interventional solutions, including 11 advanced interventional suites equipped with the Image Guided Therapy System – Azurion. The agreement also fosters clinical research opportunities and aims to improve operational efficiency and patient experiences.
On April 4, 2022, Philips (NYSE: PHG) presented significant findings at the American College of Cardiology's 71st Annual Scientific Session. A study analyzing Medicare data revealed that around 80% of patients with Cardiac Implantable Electronic Device (CIED) infections are not receiving treatment per established guidelines. The lack of adherence leads to a 32.4% mortality risk post-infection. Timely lead extraction correlates with a 42.9% reduction in death risk. Philips offers a range of Lead Management solutions aimed at improving patient outcomes.
Philips (NYSE: PHG) showcased its integrated solutions for atrial fibrillation at the EHRA 2022 Annual Meeting. Key innovations include the KODEX-EPD system, enhancing RF and cryoballoon therapies with new imaging features. Philips is committed to improving lead management and extraction processes, combating CIED infections effectively. The ePatch monitor streamlines AF diagnosis with extended wear capabilities. Atrial fibrillation, affecting approximately 37 million globally, is projected to double in prevalence over the next 40 years, highlighting the importance of Philips' advancements in cardiac care.
Royal Philips (NYSE: PHG) unveiled new cardiology innovations at the ACC 2022 conference to enhance efficiency and patient care. Key launches include the Philips Ultrasound Workspace, an AI-driven echocardiography solution, and Ambient Experience with FlexVision, aimed at reducing patient anxiety during procedures. Cardiovascular diseases continue to rise, increasing the demand for effective care tools. Philips emphasizes its commitment to improving clinical outcomes and operational efficiency within the increasingly complex healthcare environment.
Royal Philips (NYSE: PHG) announces the launch of Ultrasound Workspace, a vendor-neutral solution for automated 2D and 3D echocardiography analysis, enhancing diagnostic workflows. This AI-driven platform allows seamless access to echocardiography data via browsers, improving efficiency and diagnostic quality for cardiologists. Features include vendor-neutral capabilities and standardized user experiences across devices, facilitating better patient outcomes and operational flow. Philips aims to redefine echocardiography by integrating advanced technology into clinical workflows.
Royal Philips (NYSE: PHG) has announced the commercial launch of its Ambient Experience with FlexVision display, designed to enhance patient comfort in interventional rooms. This solution aims to reduce patient anxiety, potentially lowering the need for sedatives during procedures. By allowing staff to customize ambient lighting and sound, it creates a calming atmosphere. Evidence suggests this could lead to shorter procedure times and reduced healthcare costs. The innovation will be showcased at ACC 2022, taking place from April 2-4 in Washington, D.C.